Search research articles
Contact Us
Filters
Showing results (91-100 of 181) with videos related to
Page
of 19
Sort By:
The Journal of Investigative Dermatology
|
August 6, 2019
Peptides Derived from the Tight Junction Protein CLDN1 Disrupt the Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine
Matthew G Brewer, Elizabeth A Anderson, Radha P Pandya, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 29, 2018
Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
Xuehua Ke, Abhishek Kavati, Debra Wertz, et al.
The Journal of Investigative Dermatology
|
August 14, 2014
Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage
Andrew W Borkowski, I-Hsin Kuo, Jamie J Bernard, et al.
The Journal of Allergy and Clinical Immunology
|
October 15, 2011
Polyinosinic:polycytidylic acid induces protein kinase D-dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells
Fariba Rezaee, Nida Meednu, Jason A Emo, et al.
The Journal of Allergy and Clinical Immunology
|
May 22, 2007
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D Howell, Byung Eui Kim, Peisong Gao, et al.
The Journal of Allergy and Clinical Immunology
|
September 2, 2009
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D Howell, Byung Eui Kim, Peisong Gao, et al.
Journal of the American Academy of Dermatology
|
December 6, 2022
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial
Lisa A Beck, Thomas Bieber, Stephan Weidinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
Mark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
JAMA Dermatology
|
July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Lisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology
|
February 18, 2017
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis
Donald Y M Leung, Brett Jepson, Lisa A Beck, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 181) with videos related to
Sort By:
Page
of 19
The Journal of Investigative Dermatology
|
August 6, 2019
Peptides Derived from the Tight Junction Protein CLDN1 Disrupt the Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine
Matthew G Brewer, Elizabeth A Anderson, Radha P Pandya, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 29, 2018
Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States
Xuehua Ke, Abhishek Kavati, Debra Wertz, et al.
The Journal of Investigative Dermatology
|
August 14, 2014
Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage
Andrew W Borkowski, I-Hsin Kuo, Jamie J Bernard, et al.
The Journal of Allergy and Clinical Immunology
|
October 15, 2011
Polyinosinic:polycytidylic acid induces protein kinase D-dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells
Fariba Rezaee, Nida Meednu, Jason A Emo, et al.
The Journal of Allergy and Clinical Immunology
|
May 22, 2007
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D Howell, Byung Eui Kim, Peisong Gao, et al.
The Journal of Allergy and Clinical Immunology
|
September 2, 2009
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D Howell, Byung Eui Kim, Peisong Gao, et al.
Journal of the American Academy of Dermatology
|
December 6, 2022
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial
Lisa A Beck, Thomas Bieber, Stephan Weidinger, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
Mark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
JAMA Dermatology
|
July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Lisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology
|
February 18, 2017
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis
Donald Y M Leung, Brett Jepson, Lisa A Beck, et al.
Page
of 19